ALC.SW Alcon (SIX) closes CHF61.90 on 17 Feb 2026: earnings may set next trend

ALC.SW stock was the most active name on the SIX on 17 Feb 2026, closing at CHF61.90, up 1.48% on a volume of 1,234,565 shares. Trading stayed above the session low of CHF60.12 and near the day high of CHF61.98 as investors priced in a product launch and the company’s upcoming earnings on 24 Feb 2026. Alcon Inc. (ALC.SW) is tracked for reaction to new Vision Care releases and surgical demand, both of which can move near-term sentiment and set a direction into next week’s report.

ALC.SW stock: session snapshot and news drivers

Alcon Inc. (ALC.SW) ended the market closed session on the SIX at CHF61.90. Volume of 1,234,565 exceeded the average of 1,097,117, marking strong retail and institutional activity. The company announced the U.S. launch of TOTAL30® Multifocal for Astigmatism, a product likely to support Vision Care sales. Business Wire press release and related coverage added context for buyers ahead of the earnings date.

ALC.SW stock: valuation and key financials

Alcon reports EPS CHF1.62 and trades at a PE of 37.11 on the SIX. Revenue per share TTM stands at CHF20.65 and book value per share is CHF44.74. The company shows a free cash flow yield of 4.11% and debt to equity of 0.24, which supports balance-sheet resilience relative to peers in Healthcare. These ratios suggest premium multiple versus sector average PE of 33.83, reflecting growth expectations and product pipeline value.

ALC.SW stock: technicals and trading activity

Momentum indicators show a neutral to slightly bullish bias. RSI is 58.62 and MACD is positive at 0.49 with a histogram of 0.03. Bollinger Bands middle sits at CHF63.72. Short-term averages (50-day CHF62.98, 200-day CHF65.70) indicate recent weakness below long-term trend. Price sits between the day range CHF60.12–CHF61.98, and the stock remains 28.95% below its year high of CHF87.00.

Meyka AI rates ALC.SW with a score out of 100

Meyka AI rates ALC.SW with a score out of 100: 74.79 (Grade B+), Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model highlights steady cash flow growth, a manageable debt profile, and marketable product launches as positives. These grades are not guarantees and we are not financial advisors.

ALC.SW stock: risks and opportunities

Opportunity lies in Vision Care innovations like TOTAL30® Multifocal for Astigmatism, which addresses under-served presbyopic astigmatism. Surgical demand and IOL adoption remain upside catalysts. Risks include margin pressure, competitive pricing, and macro weakness that could reduce elective procedures. Inventory days remain elevated at 194.07, which could weigh on near-term cash conversion if sales slow.

ALC.SW stock: analyst outlook and price targets

Analyst consensus is limited, so we frame targets from fundamentals. A conservative scenario values Alcon at CHF55.00 (bear), a base case target is CHF66.00, and a bull case for recovery is CHF78.00. Rationale: steady revenue per share growth, improving operating cash flow, and a sector PE premium. Investors should watch the 24 Feb 2026 earnings for organic growth detail and margin guidance. See live metrics on Meyka’s platform for updates: Meyka ALC.SW page. For full launch details read the release on Seeking Alpha and Business Wire source and source.

Final Thoughts

ALC.SW stock closed the most active session on the SIX at CHF61.90 on 17 Feb 2026 with above-average volume, driven by the TOTAL30® Multifocal for Astigmatism launch and positioning ahead of earnings on 24 Feb 2026. Financials show modest growth, with EPS CHF1.62, PE 37.11, and a free cash flow yield of 4.11%. Meyka AI’s forecast model projects a quarterly level of CHF61.27 and a yearly level of CHF58.39, implying a near-term downside of -1.02% to the quarterly figure and -5.66% to the yearly figure versus the current price of CHF61.90. Meyka flags product innovation and surgical demand as primary upside drivers and highlights inventory and elective-procedure risks. Investors seeking exposure should watch the earnings release for revenue mix, margin guidance, and adoption metrics. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.